Globus Medical (GMED) Surpasses Q4 Earnings and Revenue Estimates

globus Medical (GMED) exited with quarterly earnings of $0.49 per share, beating Zacks consensus estimate of $0.48 per share. That compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 2.08%. A quarter ago, this medical device company was expected to post a profit of $0.45 per share when it actually produced a profit of $0.50, offering a surprise of 11.11 %.

In the past four quarters, the company has exceeded consensus EPS estimates four times.

Globus Medical, which is part of the Zacks Medical – Instruments industry, reported revenue of $250.02 million for the quarter ended December 2021, beating Zacks’ consensus estimate by 2.50%. That compares to revenues of $233.45 million a year ago. The company has exceeded consensus revenue estimates three times in the past four quarters.

The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.

Globus Medical stock has lost about 5.3% year-to-date compared to a -6.1% decline for the S&P 500.

What’s next for Globus Medical?

As Globus Medical has outperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?

There is no easy answer to this key question, but one reliable measure that can help investors answer it is the company’s earnings outlook. This includes not only current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Prior to this publication of the results, the trend of revisions of estimates for Globus Medical: favorable. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation results in a Zacks No. 2 (buy) ranking for the stock. Thus, stocks are expected to outperform the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.50 on $241.96 million in revenue for the upcoming quarter and $2.23 on $1.05 billion in revenue for the current fiscal year.

Investors should be aware that industry outlook can also have a significant impact on stock performance. In terms of Zacks industry rankings, Medical – Instruments is currently in the bottom 38% of over 250 Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.

Another stock in the same sector, OrthoPediatrics (KIDS), has not yet released its results for the quarter ended December 2021. The results are expected to be released on March 2.

This braces maker is expected to post a quarterly loss of $0.29 per share in its next report, representing a year-over-year change of +6.5%. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.

OrthoPediatrics revenue is expected to be $24.78 million, up 31% from the prior year quarter.

7 best stocks for the next 30 days

Just Released: Experts distill 7 elite stocks from the current Zacks No. 1 Ranking 220 Strong Buys list. They consider these tickers “most likely for early price increases.”

Since 1988, the full list has beaten the market more than 2 times with an average gain of +25.4% per year. So be sure to give your immediate attention to these 7 handpicked ones.

Discover them now >>

Click to get this free report

Globus Medical, Inc. (GMED): Free Inventory Analysis Report

OrthoPediatrics Corp. (KIDS): Free Stock Analysis Report

To read this article on, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.